Herantis Pharma 1H26 loss widens to EUR 3.32 million

• Herantis Pharma posted a net loss of EUR 3.32 million for January–June, widening from EUR 3.2 million a year earlier.
• Loss per share narrowed to EUR 0.12 from EUR 0.13, while cash and securities rose to EUR 3.51 million at June 30.
• Payroll and related expenses increased to EUR 1.17 million from EUR 1.12 million; other operating expenses eased to EUR 1.89 million from EUR 1.98 million.
• Reported positive Phase 1b biomarker data for HER-096, raised EUR 4.2 million in a directed share issue, secured an EUR 8 million Horizon Europe grant.
• CEO Antti Vuolanto said FDA feedback was encouraging; the company expects to initiate its Phase 2 study in 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Herantis Pharma Oyj published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.